Open-Label Trial of the Use of Minocycline in the Treatment of Asthma
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/27/2018 |
| Start Date: | October 1997 |
| End Date: | June 2020 |
Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma
The tetracycline minocycline has, in addition to its anti-infective properties,
anti-inflammatory properties which may be of use in the treatment of asthma. This study
evaluates the benefit of minocycline as add-on therapy for adults with asthma.
anti-inflammatory properties which may be of use in the treatment of asthma. This study
evaluates the benefit of minocycline as add-on therapy for adults with asthma.
Adult asthmatic (ages 18 to 75 years) with a history of moderate to severe persistent asthma
are given minocycline capsules as add-on therapy for treatment of asthma. Treatment is for
one year. Dosing begins at 150 mg twice daily and can increase every eight weeks by 50mg BID
to a maximum of 250 mg twice daily. This is as per patient tolerance as minocycline can cause
dizziness and stomach upset, as well as effects of liver enzymes.Patients undergo routine
blood toxicity screens every two months, at which time spirometry is performed Exclusion
criteria: pregnant women (adequate contraception in mandated) previous history of
hypersensitivity to tetracyclines, chronic liver disease Outcome measures: improvement in
FEV1 and other spirometric parameters, decrease in oral steroid requirements, change in total
serum IgE, improvement in quality of life
are given minocycline capsules as add-on therapy for treatment of asthma. Treatment is for
one year. Dosing begins at 150 mg twice daily and can increase every eight weeks by 50mg BID
to a maximum of 250 mg twice daily. This is as per patient tolerance as minocycline can cause
dizziness and stomach upset, as well as effects of liver enzymes.Patients undergo routine
blood toxicity screens every two months, at which time spirometry is performed Exclusion
criteria: pregnant women (adequate contraception in mandated) previous history of
hypersensitivity to tetracyclines, chronic liver disease Outcome measures: improvement in
FEV1 and other spirometric parameters, decrease in oral steroid requirements, change in total
serum IgE, improvement in quality of life
Inclusion Criteria:
- Adults (ages 18 to 75 yrs)
- Mild to severe asthma
- History of or current oral steroid use to control asthma atopy
Exclusion Criteria:
- Pregnant women
We found this trial at
1
site
SUNY Downstate Medical Center Formally known as The State University of New York Health Science...
Click here to add this to my saved trials
